Kemwell Biopharma’s oral solids facility in Bangalore has been in operation since 2008 and received its first EMA approval in 2008. Kemwell is pleased to announce that it has recently received approval from Health Canada to manufacture and supply oral solid dosage products from the facility to the Canadian market.
Speaking on the occasion, Anurag Bagaria, chairman and managing director, said, "This approval will give access to Kemwell’s current and prospective customers to the growing Canadian market. The approval also backs Kemwell’s commitment to becoming a global partner and providing high-quality products."
The state-of-the-art unit is currently equipped to manufacture and package two billion units and this can be further expanded to produce five billion units per annum. Kemwell already produces a wide range of products including un-coated, coated, effervescent tablets and capsules for the European, New Zealand and Australian markets and is awaiting its first USFDA audit later this year.